A detailed history of Coldstream Capital Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 62,071 shares of ABBV stock, worth $10.4 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
62,071
Previous 58,666 5.8%
Holding current value
$10.4 Million
Previous $10.1 Million 21.81%
% of portfolio
0.27%
Previous 0.25%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$163.84 - $199.33 $557,875 - $678,718
3,405 Added 5.8%
62,071 $12.3 Million
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $93,183 - $108,817
602 Added 1.04%
58,666 $10.1 Million
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $478,660 - $545,389
2,995 Added 5.44%
58,064 $10.6 Million
Q4 2023

Feb 09, 2024

BUY
$137.6 - $154.97 $309,324 - $348,372
2,248 Added 4.26%
55,069 $8.53 Million
Q3 2023

Nov 02, 2023

BUY
$133.59 - $154.65 $245,672 - $284,401
1,839 Added 3.61%
52,821 $7.87 Million
Q2 2023

Aug 03, 2023

SELL
$132.51 - $164.9 $192,272 - $239,269
-1,451 Reduced 2.77%
50,982 $6.87 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $176,713 - $203,511
1,222 Added 2.39%
52,433 $8.36 Million
Q4 2022

Jan 10, 2023

SELL
$138.31 - $165.87 $604,414 - $724,851
-4,370 Reduced 7.86%
51,211 $0
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $1.28 Million - $1.62 Million
9,284 Added 20.05%
55,581 $8.51 Million
Q2 2022

Aug 08, 2022

SELL
$137.62 - $174.96 $968,844 - $1.23 Million
-7,040 Reduced 13.2%
46,297 $7.09 Million
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $320,975 - $398,240
-2,432 Reduced 4.36%
53,337 $8.65 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $1.57 Million - $1.98 Million
14,601 Added 35.47%
55,769 $7.55 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $43,730 - $49,640
-411 Reduced 0.99%
41,168 $3.61 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $86,693 - $96,581
824 Added 2.02%
41,579 $4.68 Million
Q1 2021

Jun 16, 2021

BUY
$102.3 - $112.62 $3 Million - $3.3 Million
29,286 Added 255.35%
40,755 $4.41 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $2.12 Million - $2.87 Million
-26,370 Reduced 69.69%
11,469 $1.23 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $16,065 - $18,855
-187 Reduced 0.49%
37,839 $3.31 Million
Q2 2020

Aug 12, 2020

SELL
$73.37 - $98.18 $102,057 - $136,568
-1,391 Reduced 3.53%
38,026 $3.73 Million
Q1 2020

May 27, 2020

SELL
$64.5 - $97.79 $88,945 - $134,852
-1,379 Reduced 3.38%
39,417 $3 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $108,772 - $136,097
1,508 Added 3.84%
40,796 $3.61 Million
Q3 2019

Nov 15, 2019

SELL
$62.98 - $75.72 $10,328 - $12,418
-164 Reduced 0.42%
39,288 $2.98 Million
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $44,413 - $56,770
676 Added 1.74%
39,452 $2.87 Million
Q1 2019

May 10, 2019

SELL
$77.14 - $90.79 $133,837 - $157,520
-1,735 Reduced 4.28%
38,776 $3.13 Million
Q4 2018

Feb 26, 2019

BUY
$77.85 - $96.01 $67,340 - $83,048
865 Added 2.18%
40,511 $3.74 Million
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $204,670 - $227,529
2,302 Added 6.16%
39,646 $3.75 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $45,428 - $53,752
506 Added 1.37%
37,344 $3.46 Million
Q1 2018

May 16, 2018

SELL
$92.01 - $123.21 $480,384 - $643,279
-5,221 Reduced 12.41%
36,838 $3.49 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $151,356 - $165,974
1,690 Added 4.19%
42,059 $4.07 Million
Q3 2017

Nov 15, 2017

BUY
$69.85 - $89.22 $297,840 - $380,434
4,264 Added 11.81%
40,369 $3.59 Million
Q2 2017

Aug 15, 2017

BUY
N/A
36,105
36,105 $2.62 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Coldstream Capital Management Inc Portfolio

Follow Coldstream Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coldstream Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Coldstream Capital Management Inc with notifications on news.